BioSpace News Archive

Byondis B.V. today announced that Quantum Leap Healthcare Collaborative™ (Quantum Leap) selected the company’s investigational antibody-drug conjugate (ADC) SYD985 ([vic-]trastuzumab duocarmazine) for a new investigational treatment arm in its ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer.

Synaptive Medical, a leader in robotic surgical visualization, today announced the appointment of Marc R. Buntaine as chief executive officer.

Respiratory Motion Inc. (RMI) today announced the appointment of Chas Taylor and Bob Smouse, MD, FACR to the Board of Directors, Chas Taylor has been named Chairman of the Board,

There is a constant influx of new information from various sources, but Gibson Diagnostic Labs has compiled the latest recommendations from the Centers for Medicare and Medicaid Services (CMS) and the Center for Disease Control and Prevention (CDC) for easy reference.

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today the initiation of the PROLIFT Lateral Expandable System prospective study.

New research from the University of California, San Francisco (USCF) and City of Hope in the July 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines coverage trends for circulating tumor DNA testing, also known as gene sequencing of ctDNA or “liquid biopsies.”

Sandoz Inc. today announced it has entered into a long-term agreement with Civica Rx (Civica, Inc.) to manufacture and supply critical injectable generic medicines, to help reduce supply shortages and ensure acute care settings can deliver optimal patient car

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release second quarter 2020 financial results after market close on Tuesday, August 4th, 2020.

Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that it has issued an aggregate of 5,594,593 shares of common stock at a price of $92.50 per share at the closing of the Company’s previously-announced public offering.

Avantor, Inc. announced the pricing of the previously announced private offering by its wholly-owned subsidiary, Avantor Funding, Inc., of $1.550 billion aggregate principal amount of 4.625% Senior Notes due 2028 and €400 million aggregate principal amount of 3.875% Senior Notes due 2028.